These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7775127)

  • 1. Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity.
    Díaz-Rubio E; Martín M; López-Vega JM; Casado A; Benavides A
    Invest New Drugs; 1994; 12(4):277-81. PubMed ID: 7775127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.
    Taylor SA; Rankin C; Townsend JJ; Craig JB; Vance RB; Solank DL; Brown TD; Jaeckle K;
    Invest New Drugs; 2002 Feb; 20(1):113-5. PubMed ID: 12003186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of mitonafide in solid tumors.
    Llombart M; Poveda A; Forner E; Fernández-Martos C; Gaspar C; Muñoz M; Olmos T; Ruiz A; Soriano V; Benavides A
    Invest New Drugs; 1992 Aug; 10(3):177-81. PubMed ID: 1428727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of mitonafide in non-small cell lung cancer (NSCLC).
    Casado A; Rosell R; García-Gómez R; Díaz-Rubio E; Pérez-Manga G; Font A; Benavides A; Martín M
    Invest New Drugs; 1996; 14(4):415-7. PubMed ID: 9157079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer.
    Rosell R; Carles J; Abad A; Ribelles N; Barnadas A; Benavides A; Martin M
    Invest New Drugs; 1992 Aug; 10(3):171-5. PubMed ID: 1330970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of Mitonafide in advanced and relapsed colorectal cancer.
    Abad A; Grávalos C; Font A; Molina F; Díaz-Puente MT; Fabregat X; Benavides A; Martín M
    Invest New Drugs; 1996; 14(2):223-5. PubMed ID: 8913845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
    O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
    Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
    Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
    Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of amonafide in advanced and recurrent sarcoma patients.
    Perez RP; Nash SL; Ozols RF; Comis RL; O'Dwyer PJ
    Invest New Drugs; 1992 Jul; 10(2):99-101. PubMed ID: 1500272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.
    Marshall ME; Blumenstein B; Crawford ED; Thompson IM; Craig JB; Eisenberger M; Ahmann F
    Am J Clin Oncol; 1994 Dec; 17(6):514-5. PubMed ID: 7977172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
    Leaf AN; Neuberg D; Schwartz EL; Wadler S; Ritch PS; Dutcher JP; Adams GL
    Invest New Drugs; 1997; 15(2):165-72. PubMed ID: 9220297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial.
    Mullane MR; Schilsky RL; Carroll RB; Wade JL; Kilton LJ; Blough RR; Bauman A; French SL; Benson AB
    Invest New Drugs; 1994; 12(3):267-70. PubMed ID: 7896548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
    Brown TD; Ettinger DS; Donehower RC
    J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of amonafide in patients with endometrial cancer: a Gynecologic Oncology Group Study.
    Asbury R; Blessing JA; Reid GC; McGuire WP
    Am J Clin Oncol; 1998 Aug; 21(4):406-7. PubMed ID: 9708643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.
    Asbury R; Blessing JA; Buller R; Malfetano JH; Walker J; Sevin BU
    Am J Clin Oncol; 1998 Apr; 21(2):145-6. PubMed ID: 9537200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
    Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.